title: Radioiodine treatment for malignant thyroid disease.
abstract: Radioiodine treatment for thyroid disease has been given for half a decade in Sweden. The most common indication for treatment is hyperthyroidism, when iodine uptake is high. The situation in which radioiodine treatment is used in thyroid cancer is less favourable and measures therefore have to be taken to optimize the treatment. Treatment should be performed early in the course of the disease to achieve the highest possible differentiation. Before treatment the iodine and goitrogen intake should be kept low. Stimulation of the thyrocytes by thyroid-stimulating hormone (TSH) should be high. It is conventionally achieved by thyroid hormone withdrawal rendering the patient hypothyroid, or by the recently available recombinant human TSH (rhTSH) which can be recommended for ablation of the thyroid remnant after thyroidectomy and for treatment of metastases in fragile patients unable to undergo hypothyroidism. Finally, stunning--the negative effect of a prior test dose from radioactive iodine--should be avoided.
authors.affiliation: Department of Oncology, Sahlgrenska University Hospital and Sahlgrenska Academy, Göteborg University, Göteborg, Sweden. gertrud.berg@oncology.gu.se
authors.forename: Gertrud
authors.initials: G
authors.lastname: Berg
mesh_terms: D013956:Antithyroid Agents / Q000378:metabolism; D006801:Humans; D007455:Iodine / Q000378:metabolism; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D027981:Symporters / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D013972:Thyrotropin / Q000378:metabolism; D000099209:Sodium-Iodide Symporters
chemical_list: D013956:Antithyroid Agents; D007455:Iodine; D007457:Iodine Radioisotopes; D027981:Symporters; D013972:Thyrotropin; D000099209:Sodium-Iodide Symporters